Aarti Drugs Stock Screener | Share Price & Fundamental Analysis
AARTIDRUGS
Pharmaceuticals
Screen Aarti Drugs share price with our stock screener - analyze fundamentals and track trades in your journal
Share Price NSE
₹404.95
▼
-6.00 (-1.46%)
Share Price BSE
₹404.80
▼
-6.10 (-1.48%)
Market Cap
₹3,765.80 Cr.
P/E Ratio (TTM)
15.00
P/B Ratio
2.59
EPS (TTM)
₹18.42
Dividend Yield
0.24%
Debt to Equity
0.44
52W High
₹545.05
52W Low
₹321.75
Operating Margin
14.00%
Profit Margin
9.28%
Revenue (TTM)
₹679.00
EBITDA
₹95.00
Net Income
₹63.00
Total Assets
₹2,575.00
Total Equity
₹1,369.00
Aarti Drugs Share Price History - Stock Screener Chart
Screen AARTIDRUGS historical share price movements with interactive charts. Analyze price trends and patterns.
Aarti Drugs Company Profile - Fundamental Screener
Screen Aarti Drugs company fundamentals and business profile. Use our stock screener to analyze sector, industry, and key company metrics for AARTIDRUGS shares.
Sector
Healthcare
Industry
Pharmaceuticals
Sub-Sector
Pharmaceuticals
Segment
E
ISIN
INE767A01016
Aarti Drugs Balance Sheet Screener - Fundamental Analysis
Fair Value AnalysisScreen AARTIDRUGS balance sheet fundamentals including assets, liabilities, and equity. Use our screener tool to analyze financial health and share price valuation metrics.
| Item | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Assets | ||||||||||
| Total Assets | 2,575 | 2,432 | 2,421 | 2,208 | 1,766 | 1,577 | 1,456 | 1,389 | 1,191 | 1,102 |
| Current Assets | 1,338 | 1,321 | 1,492 | 1,393 | 1,057 | 900 | 784 | 737 | 571 | 565 |
| Fixed Assets | 866 | 811 | 676 | 690 | 665 | 644 | 625 | 602 | 581 | 493 |
| Liabilities | ||||||||||
| Total Liabilities | 2,575 | 2,432 | 2,421 | 2,208 | 1,766 | 1,577 | 1,456 | 1,389 | 1,191 | 1,102 |
| Current Liabilities | 368 | 355 | 279 | 232 | 257 | 301 | 321 | 312 | 297 | 244 |
| Non-Current Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Shareholders' Equity | ||||||||||
| Total Equity | 1,369 | 1,282 | 1,193 | 1,036 | 913 | 653 | 543 | 455 | 400 | 357 |
| Share Capital | 91 | 92 | 93 | 93 | 93 | 23 | 24 | 24 | 24 | 24 |
| Reserves & Surplus | 1,278 | 1,190 | 1,100 | 944 | 820 | 629 | 520 | 432 | 376 | 333 |
Screen AARTIDRUGS income statement and profit fundamentals. Analyze revenue growth, EBITDA, net profit margins, and EPS using our fundamental screener for share price evaluation.
| Item | 2025-Mar | 2025-Jun | 2025-Sept | 2024-Mar | 2024-Jun | 2024-Sept | 2024-Dec | 2023-Mar | 2023-Jun | 2023-Sept | 2023-Dec | 2022-Mar | 2022-Jun | 2022-Sept | 2022-Dec |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 679 | 591 | 653 | 621 | 557 | 600 | 569 | 743 | 662 | 642 | 608 | 697 | 622 | 688 | 665 |
| Expenses | 583 | 516 | 569 | 534 | 490 | 531 | 495 | 649 | 577 | 565 | 536 | 608 | 555 | 614 | 593 |
| EBITDA | 95 | 74 | 84 | 87 | 66 | 69 | 74 | 94 | 85 | 77 | 72 | 89 | 67 | 74 | 72 |
| Operating Profit % | 14.00% | 13.00% | 13.00% | 14.00% | 12.00% | 11.00% | 11.00% | 13.00% | 13.00% | 12.00% | 12.00% | 12.00% | 11.00% | 11.00% | 11.00% |
| Depreciation | 15 | 15 | 16 | 14 | 13 | 14 | 14 | 13 | 13 | 13 | 13 | 13 | 13 | 13 | 13 |
| Interest | 9 | 9 | 8 | 9 | 9 | 9 | 9 | 9 | 9 | 8 | 8 | 6 | 7 | 9 | 9 |
| Profit Before Tax | 71 | 51 | 60 | 64 | 44 | 46 | 51 | 73 | 64 | 56 | 52 | 71 | 48 | 53 | 50 |
| Tax | 8 | -3 | 15 | 17 | 11 | 11 | 14 | 17 | 16 | 17 | 15 | 15 | 13 | 14 | 13 |
| Net Profit | 63 | 54 | 45 | 47 | 33 | 35 | 37 | 56 | 48 | 40 | 37 | 55 | 35 | 39 | 37 |
| EPS | 6.88 | 5.91 | 4.95 | 5.15 | 3.62 | 3.83 | 4.06 | 6.07 | 5.18 | 4.29 | 3.99 | 5.97 | 3.76 | 4.18 | 3.96 |
Aarti Drugs Cash Flow Screener - Liquidity Fundamentals
Screen AARTIDRUGS cash flow statements and liquidity fundamentals. Analyze operating, investing, and financing activities using our stock screener for share price strength assessment.
| Item | 2025-March | 2024-March | 2023-March | 2022-March | 2021-March | 2020-March | 2019-March | 2018-March | 2017-March | 2016-March |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating Activities | 245 | 359 | 133 | 70 | 155 | 251 | 143 | 70 | 175 | 133 |
| Investing Activities | -165 | -224 | -164 | -150 | -72 | -33 | -62 | -74 | -107 | -99 |
| Financing Activities | -82 | -136 | 17 | 92 | -81 | -215 | -80 | 4 | -68 | -33 |
| Net Cash Flow | -2 | -1 | -14 | 13 | 2 | 2 | 1 | 0 | 0 | 1 |
Screen AARTIDRUGS shareholding pattern and ownership fundamentals. Analyze promoter holding, institutional investors, and share distribution using our screener for informed investment decisions.
| Item | 2025-Mar | 2025-Jun | 2025-Sept | 2024-Mar | 2024-Jun | 2024-Sept | 2024-Dec | 2023-Mar |
|---|---|---|---|---|---|---|---|---|
| Promoter Holding | 55.48% | 55.22% | 54.72% | 57.13% | 55.67% | 55.64% | 55.38% | 59.58% |
| FII Holding | 2.25% | 2.26% | 2.69% | 2.56% | 2.96% | 2.50% | 2.28% | 0.00% |
| DII Holding | 9.70% | 9.94% | 9.90% | 5.99% | 7.35% | 7.84% | 8.77% | 4.09% |
| Govt Holding | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Public Holding | 23.51% | 23.69% | 23.58% | 25.11% | 24.75% | 24.80% | 24.32% | 25.72% |
| Other Holding | 9.06% | 8.89% | 9.11% | 9.20% | 9.27% | 9.21% | 9.24% | 10.61% |
| Shareholder Count | 169,761 | 160,260 | 152,252 | 157,547 | 150,218 | 190,281 | 176,006 | 169,090 |
Aarti Drugs Dividend Screener - Share Yield Analysis
Screen AARTIDRUGS dividend history and yield fundamentals. Analyze dividend payout, frequency, and returns using our stock screener for income-focused share price evaluation.
| Period | Dividend Per Share | Dividend Yield |
|---|---|---|
| 2026-March | ₹0.00 | 0.00% |
| 2025-March | ₹1.00 | 0.24% |
| 2024-March | ₹1.00 | 0.29% |
| 2023-March | ₹1.00 | 0.23% |
| 2022-March | ₹1.00 | 0.30% |
| 2021-March | ₹2.50 | 0.58% |
| 2020-March | ₹2.00 | 0.29% |
| 2019-March | ₹1.00 | 0.80% |
| 2018-March | ₹1.00 | 0.63% |
| 2017-March | ₹1.00 | 0.79% |
Aarti Drugs Index Membership - Market Screener Classification
Screen AARTIDRUGS by index membership and market classification. Filter stocks by major indices like NIFTY, SENSEX using our screener for systematic share price tracking.
Aarti Drugs Market Events Screener - Corporate Actions
Screen AARTIDRUGS market events and corporate actions affecting share price. Track splits, bonuses, buybacks, and major announcements using our stock screener for fundamental event analysis.
| Announcement Date | Record Date | Event Type | Information | Price Impact |
|---|---|---|---|---|
| Buyback | 900 | 2.86% | ||
| 2020-10-01 | Bonus | 3:1 | 3.97% | |
| Annual General Meeting | NA | 9.35% | ||
| Annual General Meeting | NA | -11.02% | ||
| 2025-11-07 | 2025-11-07 | Quarterly Result Announcement | NA | -2.61% |
| 2025-07-18 | 2025-07-18 | Quarterly Result Announcement | NA | 7.28% |
| 2025-05-06 | 2025-05-06 | Quarterly Result Announcement | NA | 0.97% |
| 2025-02-04 | 2025-02-04 | Dividend | ₹ 1.00 /share | 8.52% |
| 2025-01-29 | 2025-01-29 | Quarterly Result Announcement | NA | -8.06% |
| 2024-10-24 | 2024-10-24 | Quarterly Result Announcement | NA | -3.19% |
| 2024-02-06 | 2024-02-06 | Dividend | ₹ 1.00 /share | -2.89% |
| 2023-08-04 | 2023-08-09 | Buyback | 900 | 2.45% |
| 2023-02-08 | 2023-02-08 | Dividend | ₹ 1.00 /share | -3.11% |
| 2022-02-09 | 2022-02-10 | Dividend | ₹ 1.00 /share | 5.51% |
Aarti Drugs Competitors Screener - Peer Comparison
Screen AARTIDRUGS competitors and compare share prices across peer stocks. Use our screener to analyze sector peers, fundamentals, and relative performance for better stock selection.
| Company | Market Cap | P/E Ratio | Revenue | YoY Growth | Net Profit | RSI |
|---|---|---|---|---|---|---|
| Sun Pharmaceutical | 414,629 | 39.37 | 54,729 | 9.71% | 10,980 | 39.47 |
| Divis Laboratories | 168,599 | 67.76 | 9,712 | 18.67% | 2,191 | 44.14 |
| Torrent Pharmaceuticals | 130,620 | 60.85 | 11,539 | 6.99% | 1,911 | 62.90 |
| Cipla | 121,893 | 22.30 | 28,410 | 7.12% | 5,291 | 46.90 |
| Dr Reddys Laboratories | 103,962 | 18.24 | 33,741 | 16.73% | 5,725 | 43.77 |
| Lupin | 96,608 | 22.10 | 22,910 | 13.74% | 3,306 | 55.44 |
| Zydus Life Science | 92,161 | 18.30 | 23,511 | 18.55% | 4,615 | 44.07 |
| Mankind Pharma | 90,086 | 50.34 | 12,744 | 20.90% | 2,007 | 44.20 |
| Aurobindo Pharma | 70,050 | 20.25 | 32,346 | 9.43% | 3,484 | 49.09 |
| Alkem Laboratories | 65,599 | 27.11 | 13,458 | 3.70% | 2,216 | 38.49 |
Aarti Drugs Company Announcements - News Screener
Screen AARTIDRUGS latest company announcements and news updates. Filter stock news, results, and material events using our screener for share price impact analysis.
| Date | Update | Actions |
|---|---|---|
| 2026-01-02 | Closure of Trading Window | View |
| 2025-11-18 | Announcement under Regulation 30 (LODR)-Newspaper Publication | View |
| 2025-11-14 | Announcement under Regulation 30 (LODR)-Earnings Call Transcript | View |
| 2025-11-10 | Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Outcome | View |
| 2025-11-08 | Announcement under Regulation 30 (LODR)-Newspaper Publication | View |
| 2025-11-07 | Announcement under Regulation 30 (LODR)-Investor Presentation | View |
| 2025-11-07 | Announcement under Regulation 30 (LODR)-Press Release / Media Release | View |
| 2025-11-07 | Board Meeting Outcome for Financial Results For The Quarter And Half Year Ended September 30 2025 | View |
| 2025-11-07 | Financial Results For The Quarter And Half Year Ended September 30 2025 | View |
| 2025-10-31 | Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation | View |
| 2025-10-31 | Board Meeting Intimation for Audited Financial Results For The Quarter And Half Year Ended September 30 2025 | View |
| 2025-10-09 | Crisil ESG Rating | View |
| 2025-10-08 | Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018 | View |
| 2025-10-06 | Disclosure Under Regulation 30 Of The SEBI (Listing Obligations And Disclosure Requirements) Regulations 2015 ("Listing Regulations") | View |
| 2025-09-29 | Closure of Trading Window | View |
| 2025-09-24 | Shareholder Meeting / Postal Ballot-Scrutinizers Report | View |
| 2025-09-24 | Announcement under Regulation 30 (LODR)-Change in Management | View |
| 2025-09-24 | Announcement under Regulation 30 (LODR)-Investor Presentation | View |
| 2025-09-24 | Shareholder Meeting / Postal Ballot-Outcome of AGM | View |
| 2025-09-10 | Closure Of Chlorosulfonation Process At PTSCL Section At T-150 Unit Pursuant To Voluntary Closure Directions Of MPCB | View |